First-Line Chemotherapy for Non–Small-Cell Lung Cancer: Is There a Superior Regimen Based on Histology?
- 20 July 2008
- journal article
- editorial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 26 (21) , 3485-3486
- https://doi.org/10.1200/jco.2008.17.2056
Abstract
No abstract availableThis publication has 19 references indexed in Scilit:
- Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2008
- Multicenter, Phase II Trial of Sunitinib in Previously Treated, Advanced Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2008
- Pharmacogenomic Strategies Provide a Rational Approach to the Treatment of Cisplatin-Resistant Patients With Advanced CancerJournal of Clinical Oncology, 2007
- Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung CancerNew England Journal of Medicine, 2006
- Will We Ever Have Personalized Medicine for Non-small Cell Lung Cancer?Journal of Thoracic Oncology, 2006
- Phase III Trial of Gemcitabine Plus Carboplatin Versus Single-Agent Gemcitabine in the Treatment of Locally Advanced or Metastatic Non–Small-Cell Lung Cancer: The Swedish Lung Cancer Study GroupJournal of Clinical Oncology, 2005
- Erlotinib in Previously Treated Non–Small-Cell Lung CancerNew England Journal of Medicine, 2005
- Cellular and Pharmacogenetics Foundation of Synergistic Interaction of Pemetrexed and Gemcitabine in Human Non–Small-Cell Lung Cancer CellsMolecular Pharmacology, 2005
- Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With ChemotherapyJournal of Clinical Oncology, 2004
- Polychemotherapy in advanced non small cell lung cancer: a meta-analysisThe Lancet, 1993